Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2013

Study Completion Date

July 31, 2031

Conditions
LymphomaHodgkin's DiseaseRelapseLymphoma, Non-Hodgkin
Interventions
BIOLOGICAL

TGFbeta resistant LMP-specific CTLs

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2"

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Childrens Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00368082 - Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | Biotech Hunter | Biotech Hunter